RBC raises target for Illumina stock to USD 310
RBC Capital has maintained its Buy rating for Illumina stock and increased its price target from USD 230.00 to USD 310.00, following the company's strong second-quarter revenue of USD 1.16 billion. Despite this bullish update, the average analyst target for Illumina remains below its recent Nasdaq closing price. The stock was trading at EUR 243.68 at Lang & Schwarz and closed at USD 273.04 on Nasdaq, nearing its 52-week high.
RBC Capital raises Illumina stock price target on clinical sales By Investing.com
RBC Capital has increased its price target for Illumina (NASDAQ: ILMN) shares to $310 from $230, while maintaining an Outperform rating, citing a multiple re-rating driven by clinical sales and positive catalysts, including the company being seen as an AI beneficiary. Despite customer purchasing dynamics creating near-term noise, RBC Capital believes the underlying thesis for Illumina has strengthened. The stock has seen an 80% return over the past year and is trading near its 52-week high, with InvestingPro analysis suggesting it remains undervalued.
RBC Raises Price Target on Illumina to $310 From $230, Keeps Outperform Rating
RBC Capital Markets has increased its price target for Illumina (ILMN) to $310 from $230, while maintaining an "Outperform" rating on the stock. This adjustment reflects a more optimistic outlook for the company's future performance. The article also lists other recent analyst adjustments and news regarding Illumina.
Form 4 Illumina Inc For: 2 October By Investing.com
This article from Investing.com reports on a Form 4 filing for Illumina Inc. dated October 2. Form 4s disclose transactions made by company insiders and are important for investors to track. The article itself is brief, stating only the filing's existence and date.
Guggenheim Adjusts Price Target on Illumina to $305 From $226, Keeps Buy Rating
Guggenheim has increased its price target for Illumina (ILMN) to $305 from $226, while maintaining a "Buy" rating on the stock. This adjustment reflects a positive outlook for the genetic sequencing company. Other analysts, including Leerink Partners and Piper Sandler, have also recently raised their price targets for Illumina.
The Benchmark Matters: Evaluating TruPath Genome Beyond Individual Loci
This article evaluates the TruPath Genome technology, emphasizing the importance of comprehensive benchmarking over isolated observations. It addresses criticisms from Pacific Biosciences regarding TruPath's performance, providing a technical response by analyzing benchmark truth sets and highlighting methodological issues in PacBio's examples. The article concludes by advocating for transparent and reproducible benchmarking to assess the strengths and limitations of genomic technologies.
Illumina stock trades at EUR 239.58 as Leerink lifts target
Leerink Partners has raised its price target for Illumina (ILMN) from USD 220.00 to USD 300.00, maintaining an Outperform rating. This revision follows Illumina's strong Q2 FY26 results, which showed revenue of USD 1.16 billion and an EPS of USD 1.31, beating estimates. The stock was trading at EUR 239.58 at Lang & Schwarz, down slightly, while its recent addition to the S&P 500 adds another layer of market interest.
Illumina stock heads into the open after an 8.87 percent gain
Illumina stock saw an 8.87% gain, closing at USD 273.90 on September 24, 2026, outperforming both the Nasdaq 100 and the S&P 500. The company's performance was highlighted by strong session highs and closed against a backdrop of rising Treasury yields and Brent crude prices. This gain positioned Illumina favorably as trading opened on September 25, 2026.
Illumina stock hits 52-week high at 256.71 USD
Illumina Inc. stock has reached a new 52-week high of $256.71, marking a 176.14% increase over the past year. Despite trading at high earnings multiples, InvestingPro analysis suggests the stock is undervalued relative to its Fair Value. The company also announced a $300 million note offering to refinance existing debt, and several analyst firms have adjusted their price targets based on recent strong financial performance.
Illumina Inc Stock (ILMN) Moved Up by 7.45% on Sep 24: A Full Analysis
Illumina Inc (ILMN) stock surged by 7.45% on September 24, driven by its recent inclusion in the S&P 500, which spurred institutional buying. The company's strategic restructuring, GRAIL divestiture, and raised full-year earnings guidance also contributed to investor confidence and positive Wall Street sentiment. Despite technical indicators showing both buy signals and overbought conditions, and facing risks like valuation stretch and insider selling, the stock's momentum is fueled by strong clinical sequencing adoption and fund inflows.
Illumina stock adds 3.20 percent ahead of the open
Illumina stock closed at USD 255.38 on September 23, 2026, gaining 3.20 percent and outperforming the S&P 500. The stock traded between USD 248.13 and USD 256.16, with a reported trading volume of 189,250 shares, and reached a new 52-week high. Illumina is scheduled to participate in the ASHG Annual Meeting from October 20-24, 2026.
Will Index Reshuffle Change Illumina (ILMN) Narrative
Illumina (ILMN) was recently added to the S&P 500 Equal Weighted Index and removed from the Russell Small Cap Comp Value Index, causing index-related trading. This shift changes its fit in asset allocation frameworks and could increase investor focus on consistent execution in clinical and oncology segments. While the index change is mechanical, the company's fundamental reliance on clinical applications, research funding, and competition pressure on pricing and margins remain key watchpoints for investors.
Illumina (NasdaqGS:ILMN) Stock Price
This article provides an overview of Illumina's (NasdaqGS:ILMN) stock price performance, fair value estimations from various analysts, and recent news and updates. It highlights the company's financial details, key business operations, and competitive landscape. The analysis includes a discussion of operational progress, regulatory challenges, and the impact of new products like NovaSeq X and SomaLogic.
Illumina Stock Is Up 133% This Year. Here’s Where It Could Go Further.
Illumina stock has surged 133% over the past year, reaching $240 by September 18, 2026, driven by consistent earnings beats and its inclusion in the S&P 500. Despite this rapid ascent, analysts' mean target price of $203 now lags behind the current stock price, and a TIKR model projects only a 13% total return by December 2030, suggesting future growth will be slower. Insider selling by Director Keith Meister, totaling over $255 million, further complicates the outlook, indicating a potential divergence between insider sentiment and market momentum.
Illumina Stock Drops 2.3% Before Monday’s S&P 500 Return; Volume Jumps Ninefold
Illumina's stock (NASDAQ: ILMN) dropped 2.3% on Friday, September 18, 2026, closing at $239.62, despite significant trading volume suggesting index-rebalance flows ahead of its S&P 500 inclusion. The company's shares are set to join the S&P 500 before Monday's opening bell, and the increased volume is attributed to passive funds adjusting their portfolios. While Illumina reported improved financials with a 9.5% rise in Q2 revenue and an upgraded full-year outlook, a decline in adjusted operating margin highlights the importance of cost control.
Illumina, Inc.(NasdaqGS:ILMN) added to S&P 500 Ex-Financials, Real Estate, Utilities and Transportation Index
Illumina, Inc. (NasdaqGS:ILMN) has been added to the S&P 500 Ex-Financials, Real Estate, Utilities and Transportation Index. This inclusion is part of several recent index changes for the company, also being added to the S&P Global 1200, S&P 500 Equal Weighted, S&P 500 Value, S&P 500 Growth, S&P 500 Health Care, and the general S&P 500 Index. Concurrently, Illumina was dropped from the S&P 1000, S&P 400 Health Care, S&P 400, and the Russell Small Cap Comp Value Index.
Illumina Names Chief Commercial Officer and Chief Legal Officer
Illumina Inc. has appointed Mike Sullivan as Chief Commercial Officer and Julie Coletti as Chief Legal Officer. These new hires bring extensive leadership experience from the life sciences, diagnostics, and medical technology sectors, aiming to strengthen Illumina's executive team and drive continued growth and customer service.
Illumina Reports Q2 2026 Results: Full Earnings Call Transcript
Illumina reported strong Q2 2026 results with revenue growth of 9.5% and EPS growth of 10%, driven by robust NovaSeq X placements and increased clinical consumables demand. The company raised its full-year 2026 guidance, expecting organic revenue growth greater than 5% and continued high single-digit growth in 2027. Strategic focus remains on expanding multi-omics capabilities, clinical market penetration, and the BioInsight platform, including the Billion Cell Atlas project.
Illumina, Inc.(NasdaqGS: ILMN) dropped from Russell Small Cap Comp Value Index
Illumina, Inc. (NasdaqGS: ILMN) has been removed from the Russell Small Cap Comp Value Index. This news, published on September 17, 2026, is part of recent updates for the company, which also includes executive movements and analyst rating changes. Illumina specializes in DNA sequencing and array-based technologies for various life science and clinical applications.
Illumina stock reaches 52-week high at 231.82 USD
Illumina Inc (ILMN) stock has hit a new 52-week high of $231.82, reflecting a 126.57% increase over the past year. Despite its strong performance and a robust gross profit margin, InvestingPro analysis suggests the stock is currently overvalued. The company recently announced a $300 million note offering to refinance debt, while analysts have offered mixed ratings and revised price targets based on recent financial results.
Illumina Jumps 5.2% Amid Sector-Wide Rally
Illumina's stock surged 5.2% to $219.11 on Tuesday, participating in a broad sector-wide rally among diagnostics and research companies. This move, which saw other major players like TMO, WST, and MEDP also gain, indicates a positive shift in sentiment towards the broader industry. Despite recent headwinds, Illumina's strong performance suggests continued investor interest, though the rally's sustainability will depend on continued sector momentum.
Evaluating new approaches for rare disease research
This article discusses the evaluation of Illumina's TruPath technology by Marcel Nelen, Head of Genome Diagnostics at UMC Utrecht, for rare disease research. Nelen highlights the technology's novel attributes, such as direct library preparation on the flow cell and proximity-based phasing using native DNA, which significantly streamline workflows and improve data accuracy. The interview emphasizes TruPath's potential to reduce the need for parental samples and consolidate multiple complex workflows into a more simplified, generic process for clinical genomics research.
Advancing whole-genome sequencing with long-range data
Illumina's TruPath™ Genome system is introduced as a revolutionary whole-genome sequencing (WGS) solution that combines short-read accuracy with long-range insights. This system simplifies the research workflow, requiring only 10 minutes of hands-on time, and effectively resolves challenging genomic regions, structural variants, and phased variant calls across the human genome. It promises high-accuracy variant calling, improved precision for SNVs, indels, and SVs, and ultra-long phasing with SV visualization, setting a new standard for sophisticated human WGS.
This Illumina Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday
Top Wall Street analysts have issued upgrades for five companies, including Illumina, Inc., Sagimet Biosciences Inc., Figure Technology Solutions, Inc., Martin Marietta Materials, Inc., and Waters Corporation. Notably, UBS analyst Doug Schenkel turned bullish on Illumina, upgrading it from Neutral to Buy and significantly increasing its price target. These upgrades reflect positive shifts in analyst outlooks for these companies.
UBS Upgrades Illumina to Buy From Neutral, Adjusts Price Target to $260 From $135
UBS has upgraded its rating for Illumina (ILMN) from "Neutral" to "Buy" and significantly increased its price target from $135 to $260. This upgrade comes as Illumina is set to join the S&P 500 in the September rebalance, alongside Bloom Energy and Everpure. The article also mentions recent insider share sales and other analyst activities, including RBC raising its price target to $230 from $170.
Bloom Energy, Everpure, Illumina to Join S&P 500 in September Rebalance
Bloom Energy, Everpure, and Illumina are slated to be added to the S&P 500 index during its September rebalance. The article, published by MT Newswires, indicates this significant change for the companies involved. Full details are reserved for members of the platform.
Illumina and Everpure to Join S&P 500 in September Rebalancing: What it Means for Investors
Illumina, Inc. (ILMN) and Everpure, Inc. (P) are set to join the S&P 500 in September, replacing Builders FirstSource and The Trade Desk. This inclusion is expected to generate institutional buying from index-tracking funds, providing a technical boost and increased visibility for both companies. However, the long-term stock performance will depend on their underlying fundamentals, such as revenue growth and cash generation, after the initial rebalancing impact fades.
Bloom Energy, Illumina and Everpure set to join S&P 500 before Sept. 21 open
Bloom Energy Corp., Illumina Inc., and Everpure Inc. are slated to join the S&P 500 index before the market opens on September 21, replacing Molson Coors Beverage Co., Trade Desk Inc., and Builders FirstSource Inc. This rebalance led to an immediate after-hours stock bump for the incoming companies: Bloom Energy rose 6%, Illumina 1.7%, and Everpure 2.2%. The inclusion criteria for the S&P 500 require a market value of at least $22.7 billion, along with profitability, liquidity, and share-float thresholds.
Bloom Energy, Illumina, and Everpure set to join S&P 500 in quarterly rebalance
Bloom Energy, Illumina, and Everpure Inc. will be added to the S&P 500 index as part of a quarterly rebalance, leading to a surge in their stock prices. These additions will replace Molson Coors Beverage Co., The Trade Desk Inc., and Builders FirstSource Inc., which will migrate to smaller-cap indices. The reshuffling also includes changes across other S&P indices, impacting investor portfolios.
Bloom Energy, Illumina, and Everpure set to join S&P 500 in quarterly rebalance
Bloom Energy Corp., Illumina Inc., and Everpure Inc. are set to join the S&P 500 index as part of a quarterly rebalance, leading to significant after-hours stock rallies for the companies. This move will see them replace Molson Coors Beverage Co., The Trade Desk Inc., and Builders FirstSource Inc., with broader index changes also affecting the S&P MidCap 400 and S&P SmallCap 600. The reshuffling aims to ensure the index constituents accurately represent their respective market capitalization tiers.
The Market Just Told You Which Layer Of AI Biology It Is Paying For
The article discusses the recent earnings season in life sciences technology, highlighting that the market is rewarding companies that own proprietary data and systems of record in AI biology, rather than those solely selling model-informed software or AI-native discovery capabilities without a strong commercial engine. It analyzes the performance of MindWalk Holdings Corp., Veeva Systems Inc., Certara, Inc., and Recursion Pharmaceuticals, Inc. to illustrate this trend, suggesting that value accrues to the foundational biological context layer that underlies AI models.
Illumina Stock Is Up 82% in Six Months. The Street’s Target Still Trails It.
Illumina stock (ILMN) has surged 82% in six months, driven by accelerating clinical sequencing demand and speculation about an S&P 500 promotion. Despite this impressive rally, the average Street price target of $199 remains 11% below its current price of $223.22. TIKR’s model suggests a more modest long-term return, valuing ILMN at $259 by late 2030, implying that much of the re-rating based on improved fundamentals has already been absorbed into the share price.
Illumina (ILMN) Replaces Prior Deal With $1 Billion Revolving Credit Facility
Illumina (ILMN) has secured a new US$1 billion unsecured revolving credit facility, replacing its previous agreement. This new facility offers updated covenants and increased flexibility, aiming to provide a liquidity backstop and support the company's capital structure. It allows Illumina to fund working capital and strategic projects, although the actual usage and impact on leverage will be monitored in future quarterly reports.
Illumina Inc. stock outperforms competitors on strong trading day
Illumina Inc. (ILMN) saw its stock rise by 1.74% to $223.22 on Monday, marking its fourth consecutive day of gains. This performance occurred during a mixed trading session where the Dow Jones Industrial Average increased, but the S&P 500 Index declined. The company's stock outperformed its competitors on this trading day.
Illumina (NASDAQ: ILMN) director's funds sell shares across three days
Illumina director Keith A. Meister's affiliated funds, advised by Corvex Management LP, indirectly sold a total of 679,574 shares of Illumina common stock between August 19-21, 2026. These sales occurred at weighted average prices ranging from $201.59 to $220.43 per share. Despite these indirect sales, Mr. Meister still directly holds 6,780 shares of Illumina common stock.
Illumina director Keith Meister sells $145.5m in shares
Illumina director Keith Meister sold over $145 million worth of shares in Illumina, Inc. (NASDAQ:ILMN) through multiple transactions between August 19 and August 21, 2026. These sales, involving 683,474 shares, occurred as Illumina's stock surged 80% over the past year. The transactions were managed by Corvex Management LP, where Meister controls the general partner, and follow other recent company news including a $300 million note offering and positive analyst reactions to quarterly results.
Insider Selling: Illumina (NASDAQ:ILMN) Director Sells 95,000 Shares of Stock
Illumina director Keith Meister sold 95,000 shares of the company's stock for approximately $19.3 million, reducing his direct holdings by 4.55%. Despite this insider selling, Illumina's shares are trading near their 52-week high, and the company recently surpassed quarterly earnings and revenue expectations. Analysts generally have a "Hold" rating on the stock with an average price target lower than its current trading price.
Illumina Inc. stock outperforms competitors on strong trading day
Illumina Inc. (ILMN) saw its stock advance by 2.89% to $219.40, outperforming the broader market which also had a positive trading session. The S&P 500 Index rose by 0.43% and the Dow Jones Industrial Average rose by 0.98%. This marks the third consecutive day of gains for Illumina's stock.
Illumina (NASDAQ: ILMN) backer plans new multi-million-dollar stock sale
Corvex Management, an affiliate of an Illumina director, has filed to sell 250,000 shares of Illumina common stock, valued at $53.31 million, through Goldman Sachs & Co. LLC. These shares were acquired between October 2023 and March 2025. This move follows several other significant sales by Corvex Management over the past three months.
Christensen Jakob Wedel Sells 1,033 Shares of Illumina (NASDAQ:ILMN) Stock
Illumina SVP Christensen Jakob Wedel sold 1,033 shares of the company's stock for approximately $197,840, reducing his direct ownership by 6.86% to 14,023 shares. This transaction was part of a pre-arranged Rule 10b5-1 trading plan. Despite mixed analyst sentiment and a consensus "Hold" rating, Illumina's shares traded near their 52-week high, and the company surpassed its recent quarterly earnings and revenue expectations.
Illumina (NASDAQ: ILMN) SVP sells 1,033 shares in planned trade
Jakob Wedel Christensen, SVP, Strategy/Corp Development at Illumina (NASDAQ: ILMN), sold 1,033 shares of common stock on August 18, 2026, at a price of $191.52 per share. This transaction was conducted under a Rule 10b5-1 trading plan, and after the sale, Christensen directly holds 14,023 shares. The sale totaled approximately $198,000 and was reported in a Form 4 filing.
Illumina stock hits 52-week high at 207.1 USD
Illumina Inc. (ILMN) stock has reached a new 52-week high of $207.1 USD, reflecting a significant 108.22% increase over the past year. Despite its current trading price of $162.64 and a strong gross profit margin of 68%, InvestingPro's analysis suggests the stock remains undervalued. The company recently announced a $300 million note offering to refinance debt and has received various analyst rating changes and price target adjustments.
Illumina Inc. stock outperforms competitors on strong trading day
Illumina Inc. (ILMN) saw its stock rise by 8.87% to $205.00, outperforming the broader market. This occurred during a favorable trading session where the S&P 500 Index and Dow Jones Industrial Average also saw gains. The company's stock closed just shy of its 52-week high.
Illumina Stock Is Up 40% Since January. Should You Still Ride the Wave in 2026?
Illumina stock (ILMN) has rallied 40% since January, reaching a 52-week high of $204 before settling at $188, driven by strong Q2 results and raised guidance, particularly in its clinical sequencing business. Wall Street analysts are now playing catch-up, revising their price targets upward, although the TIKR model suggests a more measured annualized return of 7% by December 2030, valuing ILMN at $254. The core of the investment thesis remains the sustained growth in clinical sequencing, supported by the NovaSeq X and increasing consumables revenue.
Weekly Recap: Icahn Partners settlement and MiSeq i100 reagent rental
Illumina, Inc. (ILMN) recently settled litigation with Icahn Partners, with the mutual release effective August 21, 2025. Additionally, Illumina expanded its Next-Generation Sequencing (NGS) access in Italy by implementing a multi-year reagent-rental agreement for a MiSeq i100 with Devyser, which shifts capital expenditure to predictable reagent spending. This move aims to enhance NGS accessibility in the region.
Assenagon Asset Management S.A. Grows Holdings in Illumina, Inc. $ILMN
Assenagon Asset Management S.A. significantly increased its stake in Illumina, Inc. (NASDAQ:ILMN) by 188.6% in the second quarter, now holding 140,003 shares valued at approximately $24.6 million. This comes as Illumina exceeded quarterly earnings and revenue expectations and maintained its fiscal 2026 EPS guidance. Despite strong institutional ownership and positive earnings, analyst sentiment remains mixed with a "Hold" consensus, and recent insider selling activity has been notable.
ETFs Investing in Illumina, Inc. Stocks
This article lists various ETFs that hold Illumina, Inc. (ILU) stocks, providing detailed financial information for each fund. The data includes market value, weight of ILU in the ETF, issuer, management style, focus, expense ratio, assets under management (AUM), price, change percentage, relative volume, and 3-year NAV total return. The aim is to help investors find opportunities with lower risk through diversified ETF investments.
ETFs Investing in Illumina, Inc. Stocks
This article lists various ETFs that invest in Illumina, Inc. (ILU) stocks, providing key financial data for each fund such as market value, weight of ILU in the ETF, issuer, management style, expense ratio, AUM, price, change percentage, relative volume, and 3-year NAV total return. The information helps investors identify ETFs holding Illumina, Inc. to potentially diversify their investments with lower risk.
Independent Director Keith Meister Sold A Bunch Of Shares In Illumina
Independent Director Keith Meister recently sold US$148m worth of Illumina (NASDAQ:ILMN) stock at US$200 per share, reducing his holding by 26%. While this is the largest insider sale in the last year, it occurred at approximately the current share price, mitigating some of the negative implications of insider selling. Despite recent sales, insiders still own 2.1% of the company, valued at US$609m.
Empowered Funds LLC Increases Stock Holdings in Illumina, Inc. $ILMN
Empowered Funds LLC significantly increased its stake in Illumina, Inc. (NASDAQ:ILMN) by 104.2% in the first quarter, now holding 12,996 shares valued at approximately $1.6 million. This comes as institutional investors collectively own 89.42% of the company, and Illumina reported strong Q1 earnings, beating estimates with $1.31 EPS and $1.16 billion in revenue. Despite mixed analyst opinions and recent insider selling totaling $303.9 million, the company maintained its fiscal 2026 EPS guidance of $5.30 to $5.40.
